You are browsing the global website, which contains information intended for residents outside of the United States of America (U.S.). This website is not country-specific and therefore may contain information that is not applicable to your country.
Rare Cells, with Single Cell Precision
We offer a menu of FDA-cleared and laboratory-developed tests (LDTs) used to detect and analyze circulating tumor cells in human blood with CELLSEARCH®. This minimally invasive liquid biopsy approach allows these tests to enable optimized patient care and comfort throughout the patient’s therapeutic journey.
Learn more about our Oncology portfolio
Learn more about our commitment in cell-based noninvasive prenatal testing (CB-NIPT)
Find out more about billing options
Learn more about setting up your account and ordering a test
If you already have an existing portal account, you can login here
Discover how our clinical lab service can support biopharma partners and clinical trials
Discover how our custom research lab service can support research projects
Single Cell Analysis
FFPE Analysis
View our complete list of Laboratory Developed Tests
Read the latest news from the Menarini Group
Menarini Silicon Biosystems wants to become the indisputable leader in non-invasive cell-based applications for easier, faster, and more precise diagnostic and therapeutic approaches
Menarini Silicon Biosystems is committed to providing clinicians, pharma companies and researchers worldwide, with unparalleled cell-based products and services for advanced diagnostic solutions, through an improved understanding of rare cells and their molecular characterization
Our highest priority is to improve diagnostic and therapeutic approaches to human health by enabling, thanks to our established CELLSEARCH and DEPArray technologies, the detection and analysis of important but rare cells.
Recognized by leading centers of excellence as the industry standard for delivering 100% pure cells, our DEPArray™ image-based cell-sorting and isolation technology enables clinical researchers to conduct molecular analyses with single-cell precision, opening the door to actionable insights toward understanding each tumor’s genetic profile.
In 2017 Menarini Silicon Biosystems purchased all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) System. The integration of CELLSEARCH and DEPArray provides an end-to-end workflow solution for the enumeration, isolation, and molecular characterization of CTCs from a simple blood test in the clinical research setting.
The acquisition of CELLSEARCH represented a major milestone that reinforced the company’s strategic direction toward being a leading provider of diagnostic products and services aimed at informing the most optimal therapeutic decisions for patients with cancer.
Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.
Read More
Login